Literature DB >> 16583481

Corticosteroid treatment of refractory Kawasaki disease.

Bianca A Lang1, Rae S M Yeung, Kiem G Oen, Peter N Malleson, Adam M Huber, Mark Riley, Regan Ebbeson, Suzanne E Ramsey, Ronald M Laxer, Earl D Silverman, Brian W McCrindle, Savithiri Ratnapalan, Brian M Feldman.   

Abstract

OBJECTIVE: To review the indications for corticosteroids in patients with Kawasaki disease (KD) treated by pediatric rheumatologists in Canada and to determine their efficacy on fever in patients with refractory KD.
METHODS: All practicing pediatric rheumatologists in Canada identified KD patients treated with corticosteroids and completed a standard data form that included demographics, clinical and laboratory features, imaging studies, and therapeutic interventions, by chart review.
RESULTS: Thirty-two patients with KD (14 female; 18 male: mean age 4.6 years) were treated with corticosteroids. Corticosteroids were used in 26 patients (81%) for persistent fever despite treatment with intravenous immunoglobulin (IVIG) (refractory KD), 5 patients (19%) for congestive heart failure, and 1 patient for persistent acute phase symptoms other than fever. The 26 patients with refractory KD are the primary subject of this report. Twenty-two patients (85%) had rapid, sustained resolution of fever after corticosteroids. There were no serious reported adverse effects. Eight patients (31%) treated with corticosteroids developed coronary artery (CA) aneurysms and 9 (35%) developed CA dilatations without aneurysms. Of those who developed CA aneurysm, 4 had aneurysms detected prior to IV methylprednisolone (MP) on echocardiograms performed on days 6-27 (mean day 13) of illness. The remaining 4 patients had CA aneurysm detected after IVMP therapy, on echocardiograms performed on days 13-49 (mean day 23) of illness, 1-25 days (mean 9 days) after IVMP. In patients with one year or more of followup, 46% had resolution of CA abnormalities.
CONCLUSION: Corticosteroids are effective in the treatment of fever in most patients with IVIG-refractory KD. A multicenter prospective study is needed to determine the effect of corticosteroids on CA outcome in patients with refractory KD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583481

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Intravenous pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors:  Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

2.  Incomplete Kawasaki disease followed by systemic onset juvenile idiopathic arthritis- the diagnostic dilemma.

Authors:  Shivani Dogra; Arushi Gehlot; Deepti Suri; Amit Rawat; Rohit Manoj Kumar; Surjit Singh
Journal:  Indian J Pediatr       Date:  2012-10-10       Impact factor: 1.967

3.  Recent advances in the understanding and management of kawasaki disease.

Authors:  Anne H Rowley; Stanford T Shulman
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

4.  Predicting factors for refractory kawasaki disease.

Authors:  Young-Sun Do; Ki-Won Kim; Jin-Kyong Chun; Byung Ho Cha; Mee Kyung Namgoong; Hae Yong Lee
Journal:  Korean Circ J       Date:  2010-05-27       Impact factor: 3.243

5.  Infliximab treatment for refractory kawasaki disease in korean children.

Authors:  Min Seob Song; Sang Bum Lee; Sejung Sohn; Jin Hee Oh; Kyung Lim Yoon; Ji Whan Han; Chul Ho Kim
Journal:  Korean Circ J       Date:  2010-07-26       Impact factor: 3.243

6.  Serum IL-18 as a potential specific marker for differentiating systemic juvenile idiopathic arthritis from incomplete Kawasaki disease.

Authors:  Tadamori Takahara; Masaki Shimizu; Yasuo Nakagishi; Noriko Kinjo; Akihiro Yachie
Journal:  Rheumatol Int       Date:  2014-06-12       Impact factor: 2.631

7.  Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions.

Authors:  Dima Chbeir; Jean Gaschignard; Ronan Bonnefoy; Constance Beyler; Isabelle Melki; Albert Faye; Ulrich Meinzer
Journal:  Pediatr Rheumatol Online J       Date:  2018-07-18       Impact factor: 3.054

Review 8.  Skin signs of systemic disease in childhood.

Authors:  Amy E Gilliam
Journal:  Adv Dermatol       Date:  2006

9.  Incomplete, atypical kawasaki disease or evolving systemic juvenile idiopathic arthritis: a case report.

Authors:  Shakeel Shaikh; Sidra Ishaque; Taimur Saleem
Journal:  Cases J       Date:  2009-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.